查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971122

RNAi藥物遞送市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、材料類型、製程、階段分類

RNAi Drug Delivery Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Material Type, Process, Stage
出版日期: | 出版商: Global Insight Services | 英文 341 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

RNAi藥物遞送市場預計將從2024年的1,922億美元成長到2034年的1,1,844億美元，複合年成長率約為19.9%。 RNAi藥物傳遞市場涵蓋旨在有效遞送RNA干擾療法並增強基因靜默能力的系統。這些技術在治療遺傳性疾病、癌症和病毒感染疾病至關重要。創新主要集中在提高遞送效率、穩定性和標靶精準度。奈米技術的進步、RNAi研究投入的增加以及對個人化醫療解決方案日益成長的需求是推動該市場成長的主要因素。

RNAi藥物遞送市場正經歷強勁成長，主要得益於治療應用和創新遞送技術的進步。脂質體藥物遞送系統細分市場成長最為迅猛，主要歸功於其在提高RNAi穩定性和細胞攝取方面的有效性。脂質奈米顆粒憑藉其優異的遞送能力和生物相容性，在該細分市場中尤其引人注目。聚合物體藥物遞送系統細分市場成長速度排名第二，其優勢在於多功能性和標靶遞送的潛力。樹狀樹狀聚合物因其能夠提高藥物溶解度和降低毒性，在該細分市場中備受關注。治療應用細分市場也展現出良好的成長前景，其中腫瘤治療領域佔據主導地位，這主導歸功於癌症患者數量的不斷成長以及RNAi療法靶向特定基因突變的潛力。遺傳疾病細分市場緊隨其後，反映出人們對RNAi在治療罕見遺傳疾病方面日益成長的興趣。遞送技術的創新和治療適應症的拓展預計將推動未來市場的發展趨勢。

市場區隔
類型 奈米顆粒、脂質體、高分子奈米微胞、外泌體、適配體、樹狀聚合物、胜肽
產品 siRNA、miRNA、shRNA、dsRNA
服務 客製化合成、分析服務、配方開發、規模化生產和法規支持
科技 化學偶聯、脂質體、聚合物基遞送、生物偶聯遞送
適應症 腫瘤科、心血管疾病科、神經系統疾病科、感染疾病、代謝疾病科、遺傳性疾病科
最終用戶 製藥公司、生技公司、學術研究機構、受託研究機構
材料類型 脂質、聚合物、無機材料、胜肽
過程 包封、結合、絡合
步 藥物發現、臨床前研究、臨床研究、商業化

市場概況：

RNAi藥物遞送市場的特點是市場佔有率分佈動態變化、定價策略創新以及新產品頻繁推出。各公司不斷完善產品系列，以滿足日益成長的RNAi療法需求。這種競爭環境孕育了創新文化，定價策略經過精心設計，力求在價格可負擔性和盈利之間取得平衡。新型遞送技術的引進是推動市場發展的關鍵因素，各公司競相爭取主導。 RNAi藥物遞送市場的競爭異常激烈，主要參與者不斷相互參照，以保持競爭優勢。監管的影響至關重要，尤其是在北美和歐洲，它塑造著市場動態和合規標準。嚴格的法規結構確保了藥物的安全性和有效性，並影響打入市場策略。競爭環境的特徵是策略聯盟和收購，旨在增強技術能力和擴大市場覆蓋範圍。這種環境凸顯了合規性和策略性定位對於永續成長的重要性。

主要趨勢和促進因素：

RNAi藥物遞送市場正經歷強勁成長，主要得益於奈米技術和標靶遞送系統的進步。這些創新提高了RNAi療法的精準性和療效，增強了治療效果，同時減少了脫靶效應。慢性病和遺傳性疾病的日益普遍推動了對基於RNAi的解決方案的需求，這些方案為傳統治療方法不足的領域提供了新的治療途徑。此外，個人化醫療的興起，結合RNAi技術，正在促進根據每個人的基因譜制定個人化治療方案。 RNAi療法監管核准的加速進一步驗證了其潛力，並支持了該領域的投資。生技公司與學術機構之間的合作正在推動研究，並引領RNAi應用領域的突破。此外，新興市場不斷擴大的醫療基礎設施也為市場參與者提供了盈利的機會。專注於成本效益高的遞送機制和可擴展生產流程的公司，將更有利於滿足這一不斷成長的需求。這些趨勢和促進因素預計將顯著擴大RNAi藥物遞送市場，並變革醫療保健產業。

限制與挑戰：

目前，RNAi藥物遞送市場面臨許多重大限制與挑戰。其中一個主要問題是遞送系統的複雜性。開發高效安全的遞送機制仍然是一項重大的科學挑戰，阻礙了市場擴張。此外，監管障礙也加劇了這項挑戰。 RNAi療法的嚴格核准流程可能會延遲市場准入並增加成本。另一個挑戰是RNAi藥物的高生產成本。這些成本會限制其可近性並抑制投資。智慧財產權問題也構成重大障礙。專利糾紛與授權問題有可能扼殺產業內的創新與合作。此外，市場也面臨其他治療技術的競爭。其他治療方法（例如CRISPR）的快速發展正在分散人們對RNAi的關注和資源。這些因素共同限制了RNAi藥物遞送解決方案的成長潛力和廣泛應用。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 奈米顆粒
    • 脂質體
    • 聚合物膠束
    • 外泌體
    • 適體
    • 樹狀聚合物
    • 胜肽
  • 市場規模及預測：依產品分類
    • siRNA
    • 微型RNA
    • shRNA
    • dsRNA
  • 市場規模及預測：依服務分類
    • 客製合成
    • 分析服務
    • 配方開發
    • 擴大規模
    • 監管支持
  • 市場規模及預測：依技術分類
    • 化學鍵
    • 脂質奈米顆粒
    • 基於聚合物的遞送
    • 生物複合物遞送
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 神經系統疾病
    • 感染疾病
    • 代謝性疾病
    • 遺傳性疾病
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 學術研究機構
    • 合約研究機構
  • 市場規模及預測：依材料類型分類
    • 脂質
    • 聚合物
    • 無機材料
    • 胜肽
  • 市場規模及預測：依製程分類
    • 封裝技術
    • 加入
    • 錯合的形成
  • 市場規模及預測：依發展階段分類
    • 藥物發現
    • 臨床前階段
    • 臨床
    • 商業的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Silence Therapeutics
  • Dicerna Pharmaceuticals
  • Arcturus Therapeutics
  • Marina Biotech
  • Benitec Biopharma
  • RXi Pharmaceuticals
  • Bio-Path Holdings
  • Quark Pharmaceuticals
  • Sirnaomics
  • OliX Pharmaceuticals
  • Genevant Sciences
  • Regulus Therapeutics
  • Calando Pharmaceuticals

第9章：關於我們

簡介目錄
Product Code: GIS34222

RNAi Drug Delivery Market is anticipated to expand from $192.2 billion in 2024 to $1,184.4 billion by 2034, growing at a CAGR of approximately 19.9%. The RNAi Drug Delivery Market encompasses systems designed to deliver RNA interference therapeutics effectively within the body, enhancing gene silencing capabilities. These technologies are pivotal in treating genetic disorders, cancers, and viral infections. Innovations focus on improving delivery efficiency, stability, and targeting precision. The market is driven by advancements in nanotechnology, increased investment in RNAi research, and a growing demand for personalized medicine solutions.

The RNAi Drug Delivery Market is experiencing robust growth, propelled by advancements in therapeutic applications and innovative delivery technologies. The lipid-based delivery systems segment is the top performer, driven by its efficacy in enhancing RNAi stability and cellular uptake. Within this segment, lipid nanoparticles are particularly noteworthy for their superior delivery capabilities and biocompatibility. The polymer-based delivery systems segment is the second highest performing, offering versatility and potential for targeted delivery. In this segment, dendrimers are gaining attention for their ability to improve drug solubility and reduce toxicity. The therapeutic applications segment also shows promising growth, with oncology leading due to the increasing prevalence of cancer and the potential of RNAi therapies to target specific genetic mutations. The genetic disorders sub-segment follows closely, reflecting the growing interest in RNAi for treating rare genetic conditions. Innovation in delivery technologies and expanding therapeutic indications are set to drive the market's future trajectory.

Market Segmentation
TypeNanoparticles, Liposomes, Polymeric Micelles, Exosomes, Aptamers, Dendrimers, Peptides
ProductsiRNA, miRNA, shRNA, dsRNA
ServicesCustom Synthesis, Analytical Services, Formulation Development, Scale-Up, Regulatory Support
TechnologyChemical Conjugation, Lipid Nanoparticle, Polymer-Based Delivery, Bio-Conjugate Delivery
ApplicationOncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Metabolic Disorders, Genetic Disorders
End UserPharmaceutical Companies, Biotechnology Firms, Academic Research Institutes, Contract Research Organizations
Material TypeLipids, Polymers, Inorganic Materials, Peptides
ProcessEncapsulation, Conjugation, Complexation
StageDiscovery, Preclinical, Clinical, Commercial

Market Snapshot:

The RNAi Drug Delivery Market is characterized by a dynamic landscape of market share distribution, innovative pricing strategies, and frequent new product introductions. Companies are continuously enhancing their portfolios to cater to the rising demand for RNAi therapeutics. This competitive environment fosters a culture of innovation, where pricing strategies are carefully crafted to balance affordability with profitability. The introduction of novel delivery technologies is a significant driver, propelling the market forward as firms vie for leadership positions. Competition within the RNAi Drug Delivery Market is intense, with key players constantly benchmarking against each other to maintain competitive advantage. Regulatory influences, particularly in North America and Europe, are pivotal, shaping market dynamics and compliance standards. The stringent regulatory framework ensures safety and efficacy, impacting market entry strategies. The competitive landscape is marked by strategic alliances and acquisitions, aimed at enhancing technological capabilities and expanding market reach. This environment underscores the importance of regulatory navigation and strategic positioning for sustained growth.

Geographical Overview:

The RNAi drug delivery market is witnessing varied growth across regions, each presenting unique opportunities. North America leads due to advanced healthcare infrastructure and robust investments in biotechnology. The region's strong focus on research and development fosters innovation in RNAi technologies. Europe follows, with significant emphasis on personalized medicine and supportive regulatory frameworks driving market expansion. In Asia Pacific, the market is burgeoning, propelled by increasing healthcare expenditures and rapid technological advancements. Countries like China and India are emerging as key players, investing heavily in biopharmaceutical research. Latin America and the Middle East & Africa are nascent markets with growing potential. Latin America shows promise due to rising healthcare awareness and infrastructure development. Meanwhile, the Middle East & Africa are recognizing the potential of RNAi in addressing unmet medical needs, thus fueling market growth.

Key Trends and Drivers:

The RNAi Drug Delivery Market is experiencing robust growth, propelled by advancements in nanotechnology and targeted delivery systems. These innovations are enhancing the precision and efficacy of RNAi therapeutics, making treatments more effective and reducing off-target effects. The increasing prevalence of chronic diseases and genetic disorders is driving demand for RNAi-based solutions, as they offer novel therapeutic approaches where traditional methods fall short. Moreover, the rise of personalized medicine is aligning with RNAi technologies, fostering tailored treatment regimens that cater to individual genetic profiles. Regulatory approvals for RNAi therapies are accelerating, further legitimizing their potential and encouraging investment in this sector. Collaboration between biotech firms and academic institutions is spurring research, leading to breakthroughs in RNAi applications. Additionally, expanding healthcare infrastructure in emerging markets presents lucrative opportunities for market players. Companies focusing on cost-effective delivery mechanisms and scalable production processes are well-positioned to capture this growing demand. The RNAi Drug Delivery Market is poised for significant expansion as these trends and drivers converge, promising transformative impacts on healthcare.

Restraints and Challenges:

The RNAi Drug Delivery Market currently encounters several significant restraints and challenges. A primary issue is the complexity of delivery systems. Developing efficient and safe delivery mechanisms remains a formidable scientific hurdle, impeding market expansion. Furthermore, regulatory hurdles add to the challenge. The stringent approval processes for RNAi therapeutics can delay market entry and increase costs. Another challenge is the high production costs associated with RNAi drugs. These costs can limit accessibility and discourage investment. Intellectual property concerns also pose a significant barrier. Patent disputes and licensing issues can stifle innovation and collaboration within the industry. Additionally, the market faces competition from alternative therapeutic technologies. The rapid advancement of other modalities, such as CRISPR, diverts attention and resources away from RNAi. These factors collectively constrain the growth potential and broader adoption of RNAi drug delivery solutions.

Key Players:

Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Arcturus Therapeutics, Marina Biotech, Benitec Biopharma, RXi Pharmaceuticals, Bio-Path Holdings, Quark Pharmaceuticals, Sirnaomics, OliX Pharmaceuticals, Genevant Sciences, Regulus Therapeutics, Calando Pharmaceuticals

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Material Type
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Nanoparticles
    • 4.1.2 Liposomes
    • 4.1.3 Polymeric Micelles
    • 4.1.4 Exosomes
    • 4.1.5 Aptamers
    • 4.1.6 Dendrimers
    • 4.1.7 Peptides
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 siRNA
    • 4.2.2 miRNA
    • 4.2.3 shRNA
    • 4.2.4 dsRNA
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Custom Synthesis
    • 4.3.2 Analytical Services
    • 4.3.3 Formulation Development
    • 4.3.4 Scale-Up
    • 4.3.5 Regulatory Support
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Chemical Conjugation
    • 4.4.2 Lipid Nanoparticle
    • 4.4.3 Polymer-Based Delivery
    • 4.4.4 Bio-Conjugate Delivery
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurological Disorders
    • 4.5.4 Infectious Diseases
    • 4.5.5 Metabolic Disorders
    • 4.5.6 Genetic Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Firms
    • 4.6.3 Academic Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Material Type (2020-2035)
    • 4.7.1 Lipids
    • 4.7.2 Polymers
    • 4.7.3 Inorganic Materials
    • 4.7.4 Peptides
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Encapsulation
    • 4.8.2 Conjugation
    • 4.8.3 Complexation
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Discovery
    • 4.9.2 Preclinical
    • 4.9.3 Clinical
    • 4.9.4 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Material Type
      • 5.2.1.8 Process
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Material Type
      • 5.2.2.8 Process
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Material Type
      • 5.2.3.8 Process
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Material Type
      • 5.3.1.8 Process
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Material Type
      • 5.3.2.8 Process
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Material Type
      • 5.3.3.8 Process
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Material Type
      • 5.4.1.8 Process
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Material Type
      • 5.4.2.8 Process
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Material Type
      • 5.4.3.8 Process
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Material Type
      • 5.4.4.8 Process
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Material Type
      • 5.4.5.8 Process
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Material Type
      • 5.4.6.8 Process
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Material Type
      • 5.4.7.8 Process
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Material Type
      • 5.5.1.8 Process
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Material Type
      • 5.5.2.8 Process
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Material Type
      • 5.5.3.8 Process
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Material Type
      • 5.5.4.8 Process
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Material Type
      • 5.5.5.8 Process
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Material Type
      • 5.5.6.8 Process
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Material Type
      • 5.6.1.8 Process
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Material Type
      • 5.6.2.8 Process
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Material Type
      • 5.6.3.8 Process
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Material Type
      • 5.6.4.8 Process
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Material Type
      • 5.6.5.8 Process
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Alnylam Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Arrowhead Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Silence Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Dicerna Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Arcturus Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Marina Biotech
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Benitec Biopharma
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 RXi Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Bio-Path Holdings
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Quark Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sirnaomics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 OliX Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Genevant Sciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Regulus Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Calando Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us